As this report about automation in quality assurance states, ensuring optimal test coverage is among the most arduous tasks in QA. This is because the calculation of this metric depends on a plethora ...

It's the first and one of the hardest tests of the Democrats' ambitious plan to overhaul the nation's health care system: establishing a federally funded program in the next 90 days to cover people ...

Cancer test maker Lucid Diagnostics (NASDAQ:LUCD), majority owned by PavMed (NASDAQ:PAVM), traded ~8% lower on Wednesday after the company said that a group of medical experts will meet in September ...

Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...